Zinc protoporphyrin polymeric nanoparticles: Potent heme oxygenase inhibitor for cancer therapy

Pharmaceutical Research

Volumn 31, Issue 8, 2014, Pages 2124-2139

  Rouhani, Hasti ^a,b   Sepehri, Nima ^a,b   Montazeri, Hamed ^c   Khoshayand, Mohammad Reza ^d   Ghahremani, Mohammad Hossein ^a   Ostad, Seyed Nasser ^a   Atyabi, Fatemeh ^a   Dinarvand, Rassoul ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

anti cancer; heme oxygenase inhibition; PLGA nanoparticles; reactive oxygen species; zinc protoporphyrin

Indexed keywords

ANTINEOPLASTIC AGENT; HEME OXYGENASE; METAL NANOPARTICLE; POLYMER; PROTOPORPHYRIN; PROTOPORPHYRIN ZINC;

ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL SURVIVAL; DRUG EFFECTS; HUMAN; MALE; METABOLISM; MOUSE; NEOPLASMS; PARTICLE SIZE; PHYSIOLOGY; RAT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; HEME OXYGENASE (DECYCLIZING); HUMANS; MALE; METAL NANOPARTICLES; MICE; MICE, INBRED BALB C; NEOPLASMS; PARTICLE SIZE; POLYMERS; PROTOPORPHYRINS; RATS;

EID: 84893980100     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1313-7     Document Type: Article

References (43)

1. Haley B, Frenkel E, editors. Nanoparticles for drug delivery in cancer treatment. Urol Oncol: Seminars and original investigations. Elsevier; 2008.
2. Sanvicens N, Marco MP. Multifunctional nanoparticles-properties and prospects for their use in human medicine. Trends Biotechnol. 2008;26(8):425-33.
3. Oberley TD. Oxidative damage and cancer. Am J Pathol. 2002;160(2):403.
4. Poli G, Leonarduzzi G, Biasi F, Chiarpotto E. Oxidative stress and cell signalling. Curr Med Chem. 2004;11(9):1163-82.
5. Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev. 2009;35(1):32-46.
6. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004;266(1-2):37-56.
7. Kondo S, Toyokuni S, Iwasa Y, Tanaka T, Onodera H, Hiai H, et al. Persistent oxidative stress in human colorectal carcinoma, but not in adenoma. Free Radic Biol Med. 1999;27(3):401-10.
8. Was H, Dulak J, Jozkowicz A. Heme oxygenase-1 in tumor biology and therapy. Curr Drug Targets. 2010;11(12):1551-70.
9. Pervaiz S, Clement M-V. Tumor intracellular redox status and drug resistance-serendipity or a causal relationship. Curr Pharm Des. 2004;10(16):1969-77.
10. Powis G, Gasdaska JR, Baker A. Redox signaling and the control of cell growth and death. Adv Pharmacol. 1996;38:329-59.
11. Fang J, Seki T, Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev. 2009;61(4):290-302.
12. Sawa T, Wu J, Akaike T, Maeda H. Tumor-targeting chemotherapy by a xanthine oxidase-polymer conjugate that generates oxygen-free radicals in tumor tissue. Cancer Res. 2000;60(3):666-71.
13. Fang J, Sawa T, Akaike T, Maeda H. Tumor-targeted delivery of polyethylene glycol-conjugated D-amino acid oxidase for antitumor therapy via enzymatic generation of hydrogen peroxide. Cancer Res. 2002;62(11):3138-43.
14. Kinobe RT, Dercho RA, Nakatsu K. Inhibitors of the heme oxygenase-carbon monoxide system: on the doorstep of the clinic. Can J Physiol Pharmacol. 2008;86(9):577-99.
15. Fang J, Akaike T, Maeda H. Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment. Apoptosis. 2004;9(1):27-35.
16. Sahoo S, Sawa T, Fang J, Tanaka S, Miyamoto Y, Akaike T, et al. Pegylated zinc protoporphyrin: a water-soluble heme oxygenase inhibitor with tumor-targeting capacity. Bioconjug Chem. 2002;13(5):1031-8.
17. Fang J, Sawa T, Akaike T, Akuta T, Sahoo SK, Khaled G, et al. In vivo antitumor activity of Pegylated zinc protoporphyrin targeted inhibition of heme oxygenase in solid tumor. Cancer Res. 2003;63(13):3567-74.
18. Fang J, Sawa T, Akaike T, Greish K, Maeda H. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int J Cancer. 2004;109(1):1-8.
19. Iyer AK, Greish K, Fang J, Murakami R, Maeda H. High-loading nanosized micelles of copoly (styrene-maleic acid)-zinc protoporphyrin for targeted delivery of a potent heme oxygenase inhibitor. Biomaterials. 2007;28(10):1871-81.
20. Iyer AK, Greish K, Seki T, Okazaki S, Fang J, Takeshita K, et al. Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation. J Drug Target. 2007;15(7-8):496-506.
21. Regehly M, Greish K, Rancan F, Maeda H, Böhm F, Röder B. Water-soluble polymer conjugates of ZnPP for photodynamic tumor therapy. Bioconjug Chem. 2007;18(2):494-9.
22. Ding H, Sumer BD, Kessinger CW, Dong Y, Huang G, Boothman DA, et al. Nanoscopic micelle delivery improves the photophysical properties and efficacy of photodynamic therapy of protoporphyrin IX. J Control Release. 2011;151(3):271-7.
23. Fang J, Nakamura H, Iyer A. Tumor-targeted induction of oxystress for cancer therapy. J Drug Target. 2007;15(7-8):475-86.
24. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60(15):1615-26.
25. Davis ME. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771-82.
26. Dinarvand R, Sepehri N, Manoochehri S, Rouhani H, Atyabi F. Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine. 2011;6:877.
27. Maines MD. Zinc protoporphyrin is a selective inhibitor of heme oxygenase activity in the neonatal rat. Biochim et Biophys Acta (BBA)-General Subjects. 1981;673:339-50.
28. Drummond GS, Kappas A. Prevention of neonatal hyperbilirubinemia by tin protoporphyrin IX, a potent competitive inhibitor of heme oxidation. Proc Natl Acad Sci. 1981;78(10):6466-70.
29. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev. 2006;58(15):1688-713.
30. Saez A, Guzman M, Molpeceres J, Aberturas M. Freeze-drying of polycaprolactone and poly (D, L-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs. Eur J Pharm Biopharm. 2000;50(3):379-87.
31. Bozdag S, Dillen K, Vandervoort J, Ludwig A. The effect of freeze-drying with different cryoprotectants and gamma-irradiation sterilization on the characteristics of ciprofloxacin HCl-loaded poly (D, L-lactide-glycolide) nanoparticles. J Pharm Pharmacol. 2005;57(6):699-707.
32. Bilati U, Allémann E, Doelker E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci. 2005;24(1):67-75.
33. Deming SN. Multiple-criteria optimization. J Chromatogr A. 1991;550:15-25.
34. Maines MD, Kappas A. Cobalt stimulation of heme degradation in the liver. Dissociation of microsomal oxidation of heme from cytochrome P-450. J Biol Chem. 1975;250(11):4171-7.
35. Sun B, Ranganathan B, Feng S-S. Multifunctional poly (d, l-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials. 2008;29(4):475-86.
36. Esmaeili F, Dinarvand R, Ghahremani MH, Ostad SN, Esmaily H, Atyabi F. Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly (lactide-co-glycolide) nanoparticles. Anticancer Drugs. 2010;21(1):43-52.
37. Jin C, Bai L, Wu H, Song W, Guo G, Dou K. Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells. Pharm Res. 2009;26(7):1776-84.
38. Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007;28(5):869-76.
39. Hao J, Fang X, Zhou Y, Wang J, Guo F, Li F, et al. Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. Int J Nanomedicine. 2011;6:683.
40. Sabzevari A, Adibkia K, Hashemi H, Hedayatfar A, Mohsenzadeh N, Atyabi F, et al. Polymeric triamcinolone acetonide nanoparticles as a new alternative in the treatment of uveitis: In vitro and in vivo studies. Eur J Pharm Biopharm. 2013.
41. Mu L, Feng S-S. PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio. Pharm Res. 2003;20(11):1864-72.
42. Zhang L, Yang M, Wang Q, Li Y, Guo R, Jiang X, et al. 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. J Control Release. 2007;119(2):153-62.
43. Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res. 2009;26(5):1025-58.